NCT01313884 - Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Bone CancerEwing's Sarcoma

Interventions

DRUG

Irinotecan

50 mg/m2/day x 5 days

DRUG

Vincristine

2 mg/m2 to a maximum of 2 mg

DRUG

Temozolomide

100 mg/m2/day x 5 days followed by 2 weeks treatment-free

DRUG

Doxorubicin

Starting dose 75 mg/m2 to a maximum of 450mg/m2

DRUG

Cytoxan

1200 mg/m2

DRUG

Pegfilgrastim

6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle

Trial Locations (1)

Stanford University School of Medicine, Stanford